02-10-2024
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
20-08-2024
Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
13-08-2024
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
05-08-2024
Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
16-07-2024, 14:26 CEST (Ad hoc press release)
Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
26-06-2024
Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
25-06-2024
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
14-05-2024
Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
22-04-2024, 14:49 CEST (Ad hoc press release)
Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
21-03-2024
Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
19-03-2024, 19:46 CET (Ad hoc press release)
Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
31-01-2024
Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
23-01-2024
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
